ovarian cancerr – Patient Worthy

source: pixabay.com

The European Commission Just Approved MVASI, One of The First Biosimilar Cancer Drugs

Post author:James Moore
Post published:January 22, 2018
Post category:Ovarian Cancer Rare Disease Renal Cell Carcinoma

According to an article from PRNewswire, the drug MVASI (biosimilar bevacizumab) was just granted marketing authorization by the European Commission. Developed by Amgen and Allergan, this treatment has been approved…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More